Christian Karsten Hansen

Christian Karsten Hansen (born 18 August 1966) is a Danish biotechnology entrepreneur, investor and inventor, with work in new drugs, molecular biology and biochemistry.

Personal background

Originally from Copenhagen, Denmark, he spent his childhood in Antwerpen, Belgium and Caracas, Venezuela before completing high school at Sorø Academy in 1984. Following graduation as M.Sc. chemical engineering from the Technical University of Denmark in 1989,[1] PhD work in molecular biology and biochemistry was conducted at the Pasteur Institute,[2][3][4] France and the University of Salamanca,[5] Spain. He also completed an MBA from the Edinburgh Business School, Scotland.[6]

Professional background

Hansen held positions as senior scientist and director of intellectual property management at Novo Nordisk 1992–1999, and was a member of Enzyme Research Management.[6] He co-founded one of the early Danish biotechnology companies, Profound Pharma,[7][8] in 1999, with Jan Møller Mikkelsen,[9] and remained co-CEO thereof until its acquisition by Maxygen in 2000.[10] In 2001, he co-founded the investment firm Nordic Biotech Advisors,[1][11] subsequently renamed NB Capital.[12][13][14][15][16][17] Also in 2001, he founded C Hansen Invest.

Since 2001, Hansen has co-founded and/or been a board member of numerous privately held and listed biotechnology companies including Osteologix,[18][19] Nuevolution,[15][20] Curalogic,[6] Forward Pharma,[21] Rose Pharma,[22] Poalis,[15] Aditech Pharma, Veloxis Pharmaceuticals,[23] H Pharmaceuticals, Isar Pharma,[24] and ParaTech.[25]

Patents

Hansen has filed numerous patent applications in the fields of genetics of bacteria, cellulases and other enzymes, osteoporosis, and protein engineering and uses of biopharmaceuticals. He is named as inventor of issued European patents 510091,[26] 1250154,[27] 1425304,[28] 1534305,[29] 1622629,[30] 1622630,[31] 1732575,[32] 1745791[33] 2266584[34] and 2266585,[35] and US patents 5,843,720,[36] 5,916,796,[37] 6,066,473,[38] 6,555,660,[39] 6,646,110,[40] 6,831,158,[41] 7,230,081,[42] 7,232,562,[43] 7,504,237,[44] 7,550,565,[45] 7,550,566,[46] 7,595,342,[47] 7,696,153[48] and 8,541,471.[49]

Various compounds from these companies and patents are in mid and late stages of clinical development.[50][51][52][53]

gollark: How wonderful.
gollark: Although it's more "complete inability to listen to anyone competent" than "lack of maths knowledge".
gollark: Politicians who don't know maths can just ignore it and demand changes somewhere, see.
gollark: Remember, even if you only studied philosophy or politics, maths can't hurt you if you just deny it constantly or ban it, and technology people can do anything if you complain enough!
gollark: As is typical for this sort of immense stupidity this was about cryptography and them wanting magic backdoors.

References
  1. "Festglad venturekapitalist – Diverse". Business.dk. 10 November 2005. Retrieved 10 November 2011.
  2. http://jb.asm.org/cgi/reprint/174/11/3522.pdf
  3. Jørgensen Per L., Hansen Christian K., Poulsen Gitte B., Diderichsen Børge (1990). "Gene : In vivo genetic engineering: homologous recombination as a tool for plasmid construction". Gene. ScienceDirect. 96 (1): 37–41. doi:10.1016/0378-1119(90)90338-R. PMID 2265757.CS1 maint: multiple names: authors list (link)
  4. Jørgensen Per L., Hansen Christian K. (1990). "Gene : Multiple endo-β-1,4-glucanase-encoding genes from Bacillus lactus PL236 and characterization of the celB gene". Gene. ScienceDirect. 93 (1): 55–60. doi:10.1016/0378-1119(90)90135-E. PMID 2227426.
  5. Hansen, Christian K. (1992). "FEBS Letters : Fibronectin type III-like sequences and a new domain type in prokaryotic depolymerases with insoluble substrates". FEBS Letters. ScienceDirect. 305 (2): 91–96. doi:10.1016/0014-5793(92)80871-D. PMID 1618347.
  6. http://www.euroinvestor.dk/pdf/cse/140531-0.pdf
  7. "Rose Pharma – Board". Gastrotechpharma.com. Archived from the original on 21 November 2008. Retrieved 10 November 2011.
  8. "Speed, aggression, surprise!". Mva.org. Archived from the original on 28 July 2011. Retrieved 10 November 2011.
  9. "Dansk bioteks Lance Armstrong – Navne". Business.dk. 3 August 2010. Retrieved 10 November 2011.
  10. "Maxygen Reports 2000 Third quarter Financial Results. – Free Online Library". Thefreelibrary.com. Retrieved 10 November 2011.
  11. "Archived copy" (PDF). Archived from the original (PDF) on 27 July 2011. Retrieved 2011-01-17.CS1 maint: archived copy as title (link)
  12. "NB Capital". NB Capital. Retrieved 10 November 2011.
  13. "Vækstfonden – Portefølje". Vf.dk. Retrieved 10 November 2011.
  14. "European Biotechnology News :: Nordic biotech gets Euro41.5m fund". Eurobiotechnews.eu. Archived from the original on 20 July 2011. Retrieved 10 November 2011.
  15. "Danish venture capital company Nordic Biotech raises second biotech venture fund (in English)". Mva.org. Archived from the original on 11 September 2011. Retrieved 10 November 2011.
  16. "Discover Relevant Business Information". venturebeatprofiles.com. Archived from the original on 18 July 2012. Retrieved 17 January 2011.
  17. Christian Hansen PhD. "NB Capital ApS: Private Company Information – BusinessWeek". Investing.businessweek.com. Retrieved 10 November 2011.
  18. "2005 Archives". Osteologix. 29 November 2004. Retrieved 10 November 2011.
  19. http://www.osteologix.com/media/10q_2009_q2.pdf
  20. "Biotech companies in Medicon Valley popular among investors – Invest in Denmark". Investindk.com. 30 October 2007. Retrieved 10 November 2011.
  21. "Christian Hanse". Forward-pharma.com. Archived from the original on 11 July 2011. Retrieved 10 November 2011.
  22. "Archived copy". Archived from the original on 18 January 2011. Retrieved 2011-01-14.CS1 maint: archived copy as title (link)
  23. "Archived copy" (PDF). Archived from the original (PDF) on 27 June 2011. Retrieved 2011-01-17.CS1 maint: archived copy as title (link)
  24. "Isar Pharma K/S: News Release". Marketwire.com. Retrieved 10 November 2011.
  25. "Board Members | ParaTech". para-tech.dk. Archived from the original on 28 July 2017. Retrieved 28 July 2017.
  26. "Espacenet - Bibliographic data".
  27. "espacenet – Bibliographic data". V3.espacenet.com. 23 October 2002. Retrieved 10 November 2011.
  28. "espacenet – Bibliographic data". V3.espacenet.com. 9 June 2004. Retrieved 10 November 2011.
  29. "espacenet – Original document". V3.espacenet.com. Retrieved 10 November 2011.
  30. "Espacenet - Bibliographic data".
  31. "Espacenet - Bibliographic data".
  32. "espacenet – Bibliographic data". V3.espacenet.com. 20 December 2006. Retrieved 10 November 2011.
  33. "Espacenet - Bibliographic data".
  34. "Espacenet - Bibliographic data".
  35. "Espacenet - Bibliographic data".
  36. "Introduction of DNA into bacillus strains by conjugation – US Patent 5843720 Description". Patentstorm.us. Archived from the original on 11 October 2012. Retrieved 10 November 2011.
  37. "Enzyme exhibiting cellulase activity – US Patent 5916796 Full Text". Patentstorm.us. Archived from the original on 11 October 2012. Retrieved 10 November 2011.
  38. "Introduction of DNA into bacillus strains by conjugation – US Patent 6066473 Description". Patentstorm.us. Archived from the original on 11 October 2012. Retrieved 10 November 2011.
  39. "G-CSF conjugates – US Patent 6555660 Full Text". Patentstorm.us. Archived from the original on 11 October 2012. Retrieved 10 November 2011.
  40. "G-CSF polypeptides and conjugates – US Patent 6646110 Full Text". Patentstorm.us. Archived from the original on 11 October 2012. Retrieved 10 November 2011.
  41. "G-CSF conjugates – US Patent 6831158 Full Text". Patentstorm.us. Archived from the original on 11 October 2012. Retrieved 10 November 2011.
  42. "Interferon gamma conjugates – US Patent 7230081 Full Text". Patentstorm.us. Archived from the original on 11 October 2012. Retrieved 10 November 2011.
  43. "E38N interferon gamma polypeptide variants – US Patent 7232562 Full Text". Patentstorm.us. Archived from the original on 11 October 2012. Retrieved 10 November 2011.
  44. "Polynucleotides encoding interferon gamma polypeptides – US Patent 7504237 Full Text". Patentstorm.us. Archived from the original on 11 October 2012. Retrieved 10 November 2011.
  45. "G-CSF conjugates – US Patent 7550565 Full Text". Patentstorm.us. Archived from the original on 11 October 2012. Retrieved 10 November 2011.
  46. "G-CSF conjugates – US Patent 7550566 Full Text". Patentstorm.us. Archived from the original on 11 October 2012. Retrieved 10 November 2011.
  47. "Water-soluble strontium salts for use in treatment of cartilage and/or bone conditions – US Patent 7595342 Full Text". Patentstorm.us. Archived from the original on 11 October 2012. Retrieved 10 November 2011.
  48. "G-CSF conjugates – US Patent 7696153 Full Text". Patentstorm.us. Archived from the original on 11 October 2012. Retrieved 10 November 2011.
  49. http://www.patentstorm.us/patents/8541471/fulltext.html%5B%5D
  50. "News". Osteologix. 30 March 2009. Retrieved 10 November 2011.
  51. "A Dose-response Study With Strontium Malonate in Postmenopausal Women – Full Text View". ClinicalTrials.gov. Retrieved 10 November 2011.
  52. "Treatment of Neutropenia, G-CSF, Neutrophils, Chemotherapy, Protein Therapeutics, Pegylated, Clinical Trial, Neupogen, Neulasta, Blood, Bone Marrow, Breast cancer, Lung cancer, Lymphomas, Leukemias". Maxygen.com. Archived from the original on 12 October 2011. Retrieved 10 November 2011.
  53. "Evaluation of Maxy-G34 in Breast Cancer Patients Treated With TAC (Docetaxel, Adriamycin, Cyclophosphamide) Chemotherapy – Full Text View". ClinicalTrials.gov. Retrieved 10 November 2011.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.